Literature DB >> 28265124

Initiating and Managing Patients with Venous Thromboembolism on Anticoagulant Drugs: A Practical Overview.

Raj S Kasthuri1, Stephan Moll1.   

Abstract

Several new oral anticoagulants have recently been approved for the treatment of venous thromboembolism (VTE). In this review, we discuss the currently approved drugs and the factors that influence the choice of anticoagulant in a given patient. Once anticoagulation is initiated, periodic monitoring of adequacy of anticoagulation may be necessary depending on the choice of anticoagulant and patient-related factors, such as renal function. Situations that may warrant need for monitoring and the tests available for this purpose are discussed. We review reversal of anticoagulation in urgent/emergent situations as well as perioperative anticoagulation interruption in the elective setting. The data on use of direct oral anticoagulants in patients with compromised renal function, obesity and bariatric surgery, and in the treatment of cancer-associated thrombosis are discussed. The review aims to provide the clinician with the essential information to allow effective and safe use of anticoagulants for the treatment of VTE.

Entities:  

Keywords:  anticoagulation; deep vein thrombosis; direct oral anticoagulants; pulmonary embolism; venous thromboembolism

Year:  2017        PMID: 28265124      PMCID: PMC5334484          DOI: 10.1055/s-0036-1597758

Source DB:  PubMed          Journal:  Semin Intervent Radiol        ISSN: 0739-9529            Impact factor:   1.513


  22 in total

1.  Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial.

Authors:  Joshua N Goldstein; Majed A Refaai; Truman J Milling; Brandon Lewis; Robert Goldberg-Alberts; Bruce A Hug; Ravi Sarode
Journal:  Lancet       Date:  2015-02-27       Impact factor: 79.321

Review 2.  Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis.

Authors:  Maria Cristina Vedovati; Federico Germini; Giancarlo Agnelli; Cecilia Becattini
Journal:  Chest       Date:  2015-02       Impact factor: 9.410

3.  The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).

Authors:  Paul A Reilly; Thorsten Lehr; Sebastian Haertter; Stuart J Connolly; Salim Yusuf; John W Eikelboom; Michael D Ezekowitz; Gerhard Nehmiz; Susan Wang; Lars Wallentin
Journal:  J Am Coll Cardiol       Date:  2013-09-27       Impact factor: 24.094

4.  Idarucizumab for Dabigatran Reversal.

Authors:  Charles V Pollack; Paul A Reilly; John Eikelboom; Stephan Glund; Peter Verhamme; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Bushi Wang; Chak-Wah Kam; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2015-06-22       Impact factor: 91.245

5.  Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.

Authors:  Stuart J Connolly; Truman J Milling; John W Eikelboom; C Michael Gibson; John T Curnutte; Alex Gold; Michele D Bronson; Genmin Lu; Pamela B Conley; Peter Verhamme; Jeannot Schmidt; Saskia Middeldorp; Alexander T Cohen; Jan Beyer-Westendorf; Pierre Albaladejo; Jose Lopez-Sendon; Shelly Goodman; Janet Leeds; Brian L Wiens; Deborah M Siegal; Elena Zotova; Brandi Meeks; Juliet Nakamya; W Ting Lim; Mark Crowther
Journal:  N Engl J Med       Date:  2016-08-30       Impact factor: 91.245

6.  Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis.

Authors:  Xiaoli Wang; Giridhar Tirucherai; Thomas C Marbury; Jessie Wang; Ming Chang; Donglu Zhang; Yan Song; Janice Pursley; Rebecca A Boyd; Charles Frost
Journal:  J Clin Pharmacol       Date:  2015-12-22       Impact factor: 3.126

7.  Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.

Authors:  Ravi Sarode; Truman J Milling; Majed A Refaai; Antoinette Mangione; Astrid Schneider; Billie L Durn; Joshua N Goldstein
Journal:  Circulation       Date:  2013-08-09       Impact factor: 29.690

8.  Practical management of patients on apixaban: a consensus guide.

Authors:  Christopher Ward; Greg Conner; Geoffrey Donnan; Alexander Gallus; Simon McRae
Journal:  Thromb J       Date:  2013-12-31

Review 9.  Guidance for the prevention and treatment of cancer-associated venous thromboembolism.

Authors:  Alok A Khorana; Marc Carrier; David A Garcia; Agnes Y Y Lee
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300

Review 10.  The epidemiology of venous thromboembolism.

Authors:  John A Heit; Frederick A Spencer; Richard H White
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.